VivoSeq
Other

Adalimumab

2

Pipeline Programs↗

0

Active Trials↗

7

Companies Involved↗

Adalimumab is an early-stage landscape with 2 programs across 7 companies. The most active players are Amgen, AbbVie, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

2 programs

Phase 1AbbVie logo

AbbVie

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalM

Meiji Seika Pharma Co., Ltd.

0 programs

PreclinicalShanghai Henlius Biotech logo

Shanghai Henlius Biotech

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Abp 501-Hcf

Amgen

Abp 501-Lcf

Amgen

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

33

clinical trials

Completed27 · 82%
Unknown status4 · 12%
Withdrawn1 · 3%
Terminated1 · 3%

Clinical Trials

Trial Activity

33 trials

Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)
Completed·Pfizer logoPfizer·Phase 1·NCT01870986·210 enrolled
ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)
Completed·UUniversity of Leeds·Phase 2·NCT04154852·22 enrolled
A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease
Completed·AbbVie logoAbbVie·Phase 3·NCT01243671·20 enrolled
A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects
Completed·MMeiji Seika Pharma Co., Ltd.·Phase 1·NCT02927353·180 enrolled
Adalimumab Biosimilar in Clinical Practice
Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·N/A·NCT04808739·604 enrolled
Adalimumab PK Bioequivalence Study to EU and US Sourced Humira
Completed·MMylan Inc.·Phase 1·NCT02472912·270 enrolled
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))
Completed·Pfizer logoPfizer·Phase 1·NCT02237729·362 enrolled
Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.
Completed·AbbVie logoAbbVie·Phase 2·NCT01561313·64 enrolled
Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects
Completed·Shanghai Henlius Biotech logoShanghai Henlius Biotech·Phase 1·NCT03357939·220 enrolled
Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
Completed·AbbVie logoAbbVie·Phase 3·NCT00686374·100 enrolled
Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)
Completed·AAlvotech Swiss AG·Phase 1·NCT03849313·390 enrolled
Switching From Adalimumab to Infliximab
Completed·UUniversity Hospital, Ghent·N/A·NCT01338740·21 enrolled
A Clinical Study With Adalimumab Biosimilar
Completed·LLaboratorios Richmond S.A.C.I.F.·Phase 1·NCT06291948·150 enrolled
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
Completed·AbbVie logoAbbVie·Phase 4·NCT02148718·100 enrolled
Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease
Completed·GGrupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa·Phase 3·NCT01564823·86 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)